Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetirizine + pseudoephedrine is a fixed-dose combination of two small molecule drugs: cetirizine, a second-generation antihistamine, and pseudoephedrine, a sympathomimetic decongestant. This oral medication is used to treat symptoms associated with seasonal or perennial allergic rhinitis, such as nasal congestion, sneezing, runny nose, itching of the nose or throat, and watery eyes. Cetirizine works by selectively antagonizing peripheral histamine H1 receptor to block the effects of histamine released during allergic reactions. Pseudoephedrine acts as an agonist at adrenergic receptors in the nasal mucosa to constrict blood vessels and reduce swelling and congestion. The combination provides both antihistaminic relief for allergy symptoms and decongestant action for nasal stuffiness[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine + pseudoephedrine.